Treating Dyslipidemia in Type 2 Diabetes

Adam J. Nelson; Stephen J. Nicholls

doi:10.1016/j.ccl.2017.12.005

Treating Dyslipidemia in Type 2 Diabetes

Adam J. Nelson, Stephen J. Nicholls

Heart And Vascular Health

Research output: Contribution to journal › Review article › peer-review

11 Citations (Scopus)

Abstract

Type 2 diabetes is associated with elevated levels of triglycerides and small, dense low-density lipoprotein particles, in addition to low levels of high-density lipoprotein cholesterol. Clinical trials have demonstrated the clear cardiovascular benefit of use of statin therapy in patients with diabetes. Additional lipid-modifying agents are typically guided by the presence of additional lipid abnormalities. The optimal use of existing lipid agents and the potential for novel therapies in patients with diabetes is reviewed.

Original language	English
Pages (from-to)	233-239
Number of pages	7
Journal	Cardiology Clinics
Volume	36
Issue number	2
DOIs	https://doi.org/10.1016/j.ccl.2017.12.005
Publication status	Published or Issued - May 2018

Keywords

Cardiovascular risk
Clinical trials
Diabetes
Lipids

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.ccl.2017.12.005

Cite this

@article{093ee7557348475f8fcb7f96e2877dac,

title = "Treating Dyslipidemia in Type 2 Diabetes",

abstract = "Type 2 diabetes is associated with elevated levels of triglycerides and small, dense low-density lipoprotein particles, in addition to low levels of high-density lipoprotein cholesterol. Clinical trials have demonstrated the clear cardiovascular benefit of use of statin therapy in patients with diabetes. Additional lipid-modifying agents are typically guided by the presence of additional lipid abnormalities. The optimal use of existing lipid agents and the potential for novel therapies in patients with diabetes is reviewed.",

keywords = "Cardiovascular risk, Clinical trials, Diabetes, Lipids",

author = "Nelson, {Adam J.} and Nicholls, {Stephen J.}",

year = "2018",

month = may,

doi = "10.1016/j.ccl.2017.12.005",

language = "English",

volume = "36",

pages = "233--239",

journal = "Cardiology Clinics",

issn = "0733-8651",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - Treating Dyslipidemia in Type 2 Diabetes

AU - Nelson, Adam J.

AU - Nicholls, Stephen J.

PY - 2018/5

Y1 - 2018/5

N2 - Type 2 diabetes is associated with elevated levels of triglycerides and small, dense low-density lipoprotein particles, in addition to low levels of high-density lipoprotein cholesterol. Clinical trials have demonstrated the clear cardiovascular benefit of use of statin therapy in patients with diabetes. Additional lipid-modifying agents are typically guided by the presence of additional lipid abnormalities. The optimal use of existing lipid agents and the potential for novel therapies in patients with diabetes is reviewed.

AB - Type 2 diabetes is associated with elevated levels of triglycerides and small, dense low-density lipoprotein particles, in addition to low levels of high-density lipoprotein cholesterol. Clinical trials have demonstrated the clear cardiovascular benefit of use of statin therapy in patients with diabetes. Additional lipid-modifying agents are typically guided by the presence of additional lipid abnormalities. The optimal use of existing lipid agents and the potential for novel therapies in patients with diabetes is reviewed.

KW - Cardiovascular risk

KW - Clinical trials

KW - Diabetes

KW - Lipids

UR - http://www.scopus.com/inward/record.url?scp=85042214963&partnerID=8YFLogxK

U2 - 10.1016/j.ccl.2017.12.005

DO - 10.1016/j.ccl.2017.12.005

M3 - Review article

C2 - 29609753

AN - SCOPUS:85042214963

VL - 36

SP - 233

EP - 239

JO - Cardiology Clinics

JF - Cardiology Clinics

SN - 0733-8651

IS - 2

ER -

Treating Dyslipidemia in Type 2 Diabetes

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this